<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
INTROGEN THERAPEUTICS, INC.
- -------------------------------------------------------------------------------
(Exact name of Registrant as specified in its charter)
Delaware 74-2704230
- -------------------------------------------------------------------------------
(State of incorporation or organization) (I.R.S. Employer Identification No.)
301 Congress Avenue, Suite 1850, 78701
Austin, Texas
- -------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Securities to be registered pursuant to Section 12(b) of the Act:
None
- -------------------------------------------------------------------------------
Securities to be registered pursuant to Section 12(g) of the Act:
Common Stock, $0.001 par value per share
- -------------------------------------------------------------------------------
(Title of Class)
<PAGE> 2
Item 1. Description of Registrant's Securities to be Registered
Incorporated by reference to Section "Description of Capital Stock" of
the Registrant's Registration Statement on Form S-1 filed with the
Securities and Exchange Commission on September 3, 1996 (the
"Registration Statement").
Item 2. Exhibits
The following exhibits are filed as a part of this registration:
1. Form of specimen certificate for Registrant's Common Stock.*
2. Restated Certificate of Incorporation of Registrant.**
3. Bylaws of Registrant.***
____________________
* Incorporated by reference to Exhibit 4.1 to the Registration Statement.
** Incorporated by reference to Exhibit 3.2 to the Registration Statement.
*** Incorporated by reference to Exhibit 3.3 to the Registration Statement.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of
1934, the Registrant has duly caused this registration statement to be signed
on its behalf by the undersigned, thereto duly authorized.
Date: September 3, 1996 Introgen Therapeutics, Inc.
By: /s/ DAVID G. NANCE
--------------------------------
David G. Nance
President and Chief Executive Officer
